Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats

Coltart, D J; Gibson, D G; Shand, David G.

doi:10.1136/bmj.1.5747.490

Cited by 113 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, our results do not enable an MSE to be detected for propranolol at the doses used. This effect had, however, been reported at much higher doses than those used here (Coltart et al, 1971).…”

Section: Effects On Blood-pressurecontrasting

confidence: 59%

Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.

Kantelip¹,

Duchêne-Marullaz²,

Delaigue-Fabry³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Atrio‐ventricular conduction (AVC) in the unanaesthetized dog (17 animals) was studied using atrial pacing at progressively increasing frequencies applied via electrodes implanted in the right atrium. In animals habituated to the experimental conditions, beta‐adrenoceptor blocking drugs devoid of intrinsic sympathomimetic activity (ISA) modified neither heart‐rate (HR) nor AVC, though 4 mg/kg i.v. propranolol transiently raised HR and facilitated AVC. Due to their ISA, pindolol and oxprenolol raised HR and facilitated AVC at high doses. 2 Thus, when not under anaesthesia, the resting dog, in contrast to man, possesses no tonic adrenergic influence which might be suppressed by beta‐adrenoceptor blockings drugs. 3 After atropine or pentobarbitone, which considerably increased HR, beta‐adrenoceptor blocking effects became clearly visible, and the hitherto reported depressant effects on HR and AVC were observed. However, the ISA of oxprenolol, and especially of pindolol, can partly or completely mask their beta‐adrenoceptor blocking action at high doses under these experimental conditions.

show abstract

Section: Effects On Blood-pressurecontrasting

confidence: 59%

Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.

Kantelip¹,

Duchêne-Marullaz²,

Delaigue-Fabry³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Both these properties are included in the term 'membrane stabilizing activity', and there has been a great deal of controversy about its contribution to the effects of P-adrenoceptor blocking drugs in angina pectoris and in cardiac arrhythmias in man. However, the membrane stabilizing effect of propranolol has been demonstrated in vitro with human muscle only at a minimum concentration of 10 mg/l (Coltart & Meldrum, 1970) which is about 100 times greater than that required for inhibition of exercise tachycardia or suppression of ectopic beats (Coltart & Shand, 1970;Coltart, Gibson & Shand, 1971). This is, therefore, not thought to be an important property of,B-adrenoceptor blocking drugs in the doses used in clinical practice and there are no in vivo methods for demonstrating it in man.…”

Section: Membrane Stabilizing Activitmentioning

confidence: 99%

The assessment of beta‐adrenoceptor blocking drugs in man.

McDevitt¹

1977

Brit J Clinical Pharma

133

View full text Add to dashboard Cite

“…At each visit, patients were examined and a plasma sample was obtained [5][6] hours after a dose of either placebo or active drug. A 24-hour ambulatory ECG recording was obtained each week using Medcraft Accutape Holter-type recorders.…”

Section: Outpatientsmentioning

confidence: 99%

Suppression of chronic ventricular arrhythmias with propranolol.

Woosley¹,

Kornhauser²,

Smith³

et al. 1979

Circulation

132

View full text Add to dashboard Cite

SUMMARY The antiarrhythmic efficacy of propranolol was evaluated in 32 patients with chronic high frequency ventricular arrhythmias in a placebo-controlled protocol. After a placebo control period, propranolol was begun and the dosage increased sequentially until arrhythmia suppression was achieved, side effects appeared, or a maximum dosage of 960 mg/day was reached. Computerized analysis of ambulatory recordings was used to quantify the arrhythmias. Twenty-four patients had 70-100% arrhythmia suppression at plasma levels ranging from 12-1100 ng/ml (end of dosing interval). Eight patients in this group had frequent episodes of ventricular tachycardia that were totally suppressed at or below the dosage that produced >70% suppression of ventricular ectopic depolarizations (VEDs). A biphasic dose-response curve was seen in five patients who responded with a decrease in arrhythmia frequency in the lower ranges of dosages but had increased frequency of ectopic rhythms as the dosage was increased above the optimal level. Only one-third of patients

show abstract

Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats

Cited by 113 publications

References 8 publications

Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.

Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs.

The assessment of beta‐adrenoceptor blocking drugs in man.

Suppression of chronic ventricular arrhythmias with propranolol.

Contact Info

Product

Resources

About